Predictive Factors of Survival After Thalidomide Therapy in Advanced Multiple Myeloma: Long-Term Follow-Up of a Prospective Multicenter Nonrandomized Phase II Study in 120 Patients

Micro-Abstract Thalidomide monotherapy has demonstrated consistent results in the treatment of advanced multiple myeloma. We report a 9-year follow-up of a French multicenter nonrandomized phase II study that evaluated the effect of oral thalidomide in 120 patients with advanced multiple myeloma. In...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2012-12, Vol.12 (6), p.418-422
Hauptverfasser:	Decaux, Olivier, Renault, Alain, Sébille, Véronique, Moreau, Philippe, Attal, Michel, Voillat, Laurent, Pegourie, Brigitte, Tiab, Mourad, Facon, Thierry, Zerbib, Robert, Grosbois, Bernard, Bellissant, Eric
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Disease-Free Survival Female Follow-Up Studies Hematology, Oncology and Palliative Medicine Humans Male Middle Aged Multiple myeloma Multiple Myeloma - drug therapy Prognosis Prognostic factors Prospective Studies Survival Survival Analysis Thalidomide Thalidomide - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Micro-Abstract Thalidomide monotherapy has demonstrated consistent results in the treatment of advanced multiple myeloma. We report a 9-year follow-up of a French multicenter nonrandomized phase II study that evaluated the effect of oral thalidomide in 120 patients with advanced multiple myeloma. Independent predictors of survival were response to last therapy, performance status, serum β2 -microglobulin level, platelet count, and response at day 60 of treatment.
ISSN:	2152-2650 2152-2669
DOI:	10.1016/j.clml.2012.06.003